Researchers now better understand ovarian cancer tumors and treatment outcomes

After nearly four years of work, a group of researchers and clinicians from the University of Colorado (CU) published a paper this week in the Clinical Cancer Research that shares findings from research looking at how the composition of ovarian cancer tumors changes during chemotherapy and contributes to therapeutic response. While the standard of care consisting of surgery and chemotherapy […]

Read more

Experimental medication to prevent heart disease may treat chemo-resistant ovarian cancer

Most ovarian cancer starts in fallopian tubes. Then it sloughs from its site of origin and floats around in fluid until finding new sites of attachment. It’s not easy for cancer cells to survive away from their moorings. Observations by ovarian cancer doctors at University of Colorado Cancer Center and elsewhere hint at how they might do it: These doctors […]

Read more

Blood test that detects ovarian cancer could save women from surgery

Blood test that can detect ovarian cancer ‘may save lives and stop women having unnecessary surgery’ to spot the killer disease Women with ovarian cysts endure surgery to help doctors spot any tumours  For every one cancer that is detected, five women are operated on Blood test identifies 11 proteins that are higher in women with ovarian cancer  A blood […]

Read more

Antihypertension drug losartan may improve treatment of ovarian cancer

A new study from a Massachusetts General Hospital (MGH) research team has found that the hypertension drug losartan, which targets the angiotensin signaling pathway, may improve the effectiveness of chemotherapy agents used to treat ovarian cancer. Previous research from the same team identified a similar effect for losartan in animal models of breast and pancreatic cancer, leading to a phase […]

Read more

Lynparza (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer

19 December 2018 — AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza for use as maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal […]

Read more

Novel technique can potentially improve success of ovarian cancer treatment, study reveals

Novel Technique Can Potentially Improve Success of Ovarian Cancer Treatment, Study Reveals Instead of destroying a tumour’s blood supply, a first-ever University of Guelph study has proven that opening up the vessels is potentially more effective when it comes to fighting ovarian cancer. This is because open vessels provide a clear pathway for treatment to attack the tumour. “There hasn’t […]

Read more